Literature DB >> 20299966

Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations.

Sonia Rodríguez-Nóvoa1, Pablo Labarga, Antonio D'avolio, Pablo Barreiro, Marta Albalate, Eugenia Vispo, Carmen Solera, Marco Siccardi, Stefano Bonora, Giovanni Di Perri, Vincent Soriano.   

Abstract

Tenofovir (TFV) is a nucleotide analogue active against HIV and hepatitis B virus. Although TFV rarely affects the glomerular function, abnormalities in the kidney tubular function appear to be quite common. The relationship between TFV exposure and kidney tubular dysfunction (KTD) was examined prospectively in 92 HIV-infected individuals. Median TFV plasma trough concentration was higher in patients with KTD than in the rest (182 vs. 106 ng/ml; P = 0.001). This dose-dependent effect further supports an involvement of TFV in KTD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20299966     DOI: 10.1097/QAD.0b013e32833202e2

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  45 in total

Review 1.  Combination nucleoside/nucleotide reverse transcriptase inhibitors for treatment of HIV infection.

Authors:  Maxwell O Akanbi; Kimberly K Scarsi; Kimberly Scarci; Babafemi Taiwo; Robert L Murphy
Journal:  Expert Opin Pharmacother       Date:  2012-01       Impact factor: 3.889

2.  Short Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.

Authors:  Maile Young Karris
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-12       Impact factor: 2.205

Review 3.  Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.

Authors:  Atefeh Jafari; Hossein Khalili; Simin Dashti-Khavidaki
Journal:  Eur J Clin Pharmacol       Date:  2014-06-25       Impact factor: 2.953

4.  Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients.

Authors:  Pedro Rodríguez Quesada; Laura López Esteban; Jimena Ramón García; Rocío Vázquez Sánchez; Teresa Molina García; Gabriel Gaspar Alonso-Vega; Javier Sánchez-Rubio Ferrández
Journal:  Int J Clin Pharm       Date:  2015-05-26

Review 5.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

6.  Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study.

Authors:  Vincent Madelain; Minh P Le; Karen Champenois; Charlotte Charpentier; Roland Landman; Veronique Joly; Patrick Yeni; Diane Descamps; Yazdan Yazdanpanah; Gilles Peytavin
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

7.  Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.

Authors:  Monica Gandhi; David V Glidden; Kenneth Mayer; Mauro Schechter; Susan Buchbinder; Beatriz Grinsztejn; Sybil Hosek; Martin Casapia; Juan Guanira; Linda-Gail Bekker; Alexander Louie; Howard Horng; Leslie Z Benet; Albert Liu; Robert M Grant
Journal:  Lancet HIV       Date:  2016-08-31       Impact factor: 12.767

Review 8.  Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword?

Authors:  Jérôme Tourret; Gilbert Deray; Corinne Isnard-Bagnis
Journal:  J Am Soc Nephrol       Date:  2013-09-19       Impact factor: 10.121

9.  Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.

Authors:  Gautam Baheti; Jennifer R King; Edward P Acosta; Courtney V Fletcher
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

10.  Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.

Authors:  A Calcagno; D Gonzalez de Requena; M Simiele; A D'Avolio; M C Tettoni; B Salassa; G Orofino; C Bramato; V Libanore; I Motta; P Bigliano; E Orsucci; G Di Perri; S Bonora
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.